Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

  • Strategic partnership expands Biognosys’ services to include Alamar’s NULISA assays as well as joint scientific research in biofluid-based proteomics
  • Complementary value of Biognosys’ DIA-MS unbiased proteomics platform and Alamar’s game-changing immunoassay platforms to be presented at the AACR 2024 Annual Meeting

ZURICH, Switzerland and FREMONT, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomics biomarkers. This collaboration brings together Biognosys’ expertise in unbiased discovery through data independent acquisition mass spectrometry (DIA-MS) and Alamar’s cutting-edge immunoassays. This integrated approach enhances our understanding of biomarkers by combining deep unbiased DIA-MS discovery proteomics with highly specific and ultra-sensitive mid- and high-plex NULISA assays for low-abundance proteins such as cytokines, chemokines and important disease protein biomarkers from plasma.

In the Industry Spotlight Theater session hosted by Alamar at the American Society for Cancer Research (AACR) 2024 Annual Meeting in San Diego on April 9 at 12:30 pm PT, the companies will jointly present data from a collaborative study focused on Non-Small Cell Lung Cancer (NSCLC). In this study, plasma samples from a cohort of NSCLC patients were analyzed using both the Biognosys TrueDiscovery® unbiased discovery platform and Alamar’s NULISAseq™ Inflammation Panel 250. The findings demonstrate the feasibility of integrated analysis and highlight the complementary insights derived from mass spectrometry and affinity-based assays in plasma.

Building upon this successful proof-of-concept study, Biognosys and Alamar are planning to further collaborate both commercially and scientifically as part of their strategic partnership.

NULISA Assay Services: Biognosys will offer NULISA assays from its state-of-the-art facility in Switzerland for previously hard to measure cytokines, chemokines, as well as other important disease specific markers from plasma and biofluids. These ultra-high sensitivity assays enable precise quantification of low abundance proteins, providing researchers with valuable insights into complex biological processes. They complement unbiased DIA-MS analysis of thousands of plasma proteins to elucidate systemic host response, and other inflammation or disease-related protein-fold changes.Research Collaboration: Biognosys and Alamar will embark on a joint research initiative to explore plasma biology. By leveraging Biognosys’ unbiased discovery methods alongside Alamar’s ultra-high sensitivity assays, the teams seek to unravel biological disease mechanisms by providing a more complete picture of the plasma proteome, enabling for the first time the coverage of essentially the complete dynamic range of protein abundance in plasma.

Oliver Rinner, Ph.D., Founder and CEO of Biognosys, expressed enthusiasm about the collaboration: “We are excited to join forces with Alamar to advance proteomics research. Our combined efforts will pave the way for breakthroughs in plasma biology by analyzing in an unbiased way more than 5,000 proteins together with panels of hundreds of well characterized cytokines and other high value low abundance proteins using highly specific NULISA assays. With this approach we are aiming to cover the whole dynamic range of plasma proteins.”

“We are thrilled to partner with Biognosys to provide the research community with expanded access to proteomic insights from discovery through to clinical research,” said Yuling Luo, Ph.D., Chairman, Founder and CEO of Alamar. “Biognosys is a leading provider of advanced mass spec proteomics services to researchers around the world, and we look forward to adding the highest sensitivity high-multiplex immunoassays to their plasma proteomics offering.”

This partnership underscores the commitment of both companies to scientific excellence and their shared vision of advancing precision medicine through innovative technologies.

Biognosys’ DIA mass spectrometry unbiased proteomics platform


Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research
 

Biognosys’ DIA proteomics analysis software, Spectronaut® 

 

 Alamar’s NULISA™ platform: a new standard in proteomic analysis


A Media Snippet accompanying this announcement is available by clicking on this link.

About Biognosys 

At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that transform science for better lives. With our versatile portfolio of next-generation proteomics solutions, including the TrueDiscovery®, TrueTarget®, and TrueSignature® research service platforms, our flagship software Spectronaut®, and the PQ500™ kit, we make the proteome actionable to empower research, drug development, and clinical decision-making. Our solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Our unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins with industry-leading precision, depth, and throughput. Through our strategic partnership with Bruker (Nasdaq: BRKR), we make proteomics globally accessible. For more information, visit biognosys.com.

About Alamar

Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company’s proprietary NULISA Platform along with the ARGO™ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit alamarbio.com.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/b9485cd0-929f-48e9-b405-efdfbf7b5caa

https://www.globenewswire.com/NewsRoom/AttachmentNg/5eabe48a-06b5-4c37-8181-d5ff5a41a1cb


Contacts Biognosys AG  Yves Serroen Phone +41 (0) 44 244 50 07 yves.serroen@biognosys.com Alamar Biosciences, Inc Media contact: April Falcone Phone +1 (510) 838-1783 afalcone@alamarbio.com Investor contact: investors@alamarbio.com


THỦ THUẬT HAY

Hướng dẫn sửa lỗi đăng nhập iTunes/ iCloud trên Windows 10

Tìm hiểu qua trên mạng thì cũng có không ít người dùng gặp phải lỗi này với Windows 10, mình cũng đã thử nhiều cách theo gợi ý, xóa đi cài lại các kiểu vẫn không được và cuối cùng giải quyết được vấn đề theo cách đơn

Hướng dẫn kiểm tra và cập nhật phiên bản Adobe Flash Player cho máy tính

Tuy nhiên, ngoài sự tiện dụng đó thì cũng không thể phủ nhận Adobe Flash Player vẫn có những lỗi nghiêm trọng về bảo mật và đang là 'miếng mồi ngon' để kẻ xấu lợi dụng, tấn công người dùng.

ClickLock là gì? Cách bật Mouse ClickLock đơn giản và nhanh chóng trên Windows

Nếu bạn đang sử dụng chuột quá nhiều trên laptop hoặc máy tính để bàn, điều này có thể gây ra sự mệt mỏi vì phải thao tác quá nhiều. Tuy nhiên, bạn có thể giảm thiểu sự mỏi mệt này bằng cách sử dụng tính năng Mouse

Mẹo hay giúp bạn chặn ai đó trong Google Drive, hãy thử ngay

Bạn muốn chặn ai đó trong Google Drive để tránh bị làm phiền từ các email, dịch vụ, các tệp rác chia sẻ nhưng không biết làm thế nào? Trong bài này sẽ hướng dẫn cách để chặn ai đó trong Google Drive thật dễ dàng.

Hướng dẫn cách đặt vé máy bay Vietnam Airlines trực tuyến

Vietnam Airlines là hãng hàng không lớn nhất Việt Nam hiện nay và là hãng hàng không 4 sao duy nhất ở Việt Nam đáp ứng đầy đủ các điều kiện của tiêu chuẩn hàng không thế giới. Chính vì vậy giá vé của Vietnam Airlines

ĐÁNH GIÁ NHANH

Đánh giá pin Meizu M5: 3070mAh trụ được bao lâu ?

Meizu M5 có viên pin 3070mAh. Vậy thời lượng sử dụng thực tế có đáp ứng đủ nhu cầu sử dụng trong một ngày làm việc hay không? Hãy cùng FPTShop khám phá nhé.

Đánh giá camera Redmi Note 4: Có cải thiện nhưng chưa đủ

Chưa bao giờ cơn sốt Xiaomi bước chân vào Việt Nam lại hot đến vậy, điển hình là bài Redmi Note 4 của mình nhận được nhiều sự quan tâm của người...

Đánh giá chi tiết Infinix Note 3: Phablet hoàn hảo 4 triệu

Được ra mắt cùng với chiếc Hot 4, Infinix Note 3 được giao sứ mệnh là chiếc phablet 6 inch tấn công vào phân khúc dưới 4 triệu hiện nay. Thiết kế...